• Outstanding Seal
  • Antimicrobial properties
  • Promotes per-apical healing
  • Easy obturations and follow-up

BioRoot™ RCS. Succeed.

For more information on this exciting new product go to 


Article: Volume 42 Number 9 Page 878 - November 2015

Prev    Article P878    Next  Read article

  Dent Update 2015; 42: 878-889

Oral and Maxillofacial Surgery:  Periodontal Disease, Dental Implants, Extractions and Medications Related to Osteonecrosis of the Jaws

CPD:  CPD  0:24   (closed)      Self assess

Feedback:  0 comments, 0 ratings


Abstract: Patients taking bisphosphonates and other anti-resorptive drugs are likely to attend general dental practice. The term ‘bisphosphonate’ is often immediately associated with osteonecrosis of the jaws (ONJ). Risk assessment and subsequent management of these patients should be carried out taking into account all the risk factors associated with ONJ. The introduction of newer drugs, also shown to be associated with ONJ, demands increased awareness of general dental practitioners about these medications.

Clinical relevance: This paper provides an update on medication-related ONJ and considers the effects of anti-resorptive drugs on the management of patients needing exodontia, treatment for periodontal disease and dental implant placement.

Author notes: Neha P Shah, BDS, Specialty Dentist, Department of Oral Surgery, Guy's Hospital, London, Helen Katsarelis, MBChB, BDS, MRCS, Specialty Registrar, Department of Oral and Maxillofacial Surgery, Royal County Surrey Hospital, Surrey, Michael Pazianas, MD, Visiting Scholar, Institute of Musculoskeletal Sciences, Oxford University, Oxford and Daljit K Dhariwal, BDS, FDS RCS(Eng), MB BCh, FRCS(CSiG), RCS(Eng), FRCS(OMFS), Consultant, Department of Oral and Maxillofacial Surgery, John Radcliffe Hospital, Oxford, UK.

Objective: To update information on medication-related osteonecrosis of the jaws (MRONJ).